Cardiol Therapeutics' Promising Phase II Results for Pericarditis Treatment Published in Major Cardiovascular Journal

Cardiol Therapeutics' Phase II Study Results Published in JAHA

On July 14, 2026, Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL), a late-stage life sciences company specializing in heart disease therapies, announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association (JAHA). This significant development comes as the company approaches the completion of patient enrollment for its pivotal Phase III MAVERIC trial.

The results of the MAvERIC study revealed that CardiolRx™, the company’s primary small-molecule drug candidate, led to rapid and sustained reductions in pain and inflammation associated with recurrent pericarditis. For patients suffering from a severe baseline disease condition, these findings illustrated a notable decrease in the average number of pericarditis episodes experienced per year, alongside a favorable safety profile characterized by high tolerability.

David Elsley, President and CEO of Cardiol Therapeutics, expressed optimism about the publication, stating, "This peer-reviewed evidence enhances the clinical base for CardiolRx™ within the cardiovascular community. It presents comprehensive findings that were initially showcased at the American Heart Association Scientific Sessions. The data highlight critical reductions in pain, inflammation, and recurrence rates, positioning CardiolRx™ as a potentially non-immunosuppressive option for patients plagued by recurrent pericarditis."

The MAvERIC trial is designed as a randomized, double-blind, placebo-controlled study evaluating the broader implications of CardiolRx™ for reducing recurrence risks in patients experiencing pericarditis. The publication further contributes to the rationale for MAVERIC and showcases the high demand for effective treatments among affected individuals.

CardiolRx™ operates by modulating the inflammasome pathway activation, an intrinsic immune system response pivotal in the inflammation and fibrotic processes associated with heart diseases like pericarditis and myocarditis. The ongoing MAVERIC program is comprehensive, consisting of both the completed Phase II MAvERIC-Pilot study and the active Phase III trial. Recently, the U.S. FDA also granted Orphan Drug Designation to CardiolRx™ for pericarditis, validating its importance in this therapeutic area.

In addition to pericarditis, the company has initiated the ARCHER Program, which investigates CardiolRx™ for acute myocarditis—a major contributor to sudden cardiac events in younger populations.

Moreover, Cardiol is advancing CRD-38, an innovative subcutaneously administered formulation intended for treating inflammatory heart diseases, including heart failure—one of the leading causes of mortality and healthcare costs in developed countries.

With these advancements, Cardiol Therapeutics is not only pushing the boundaries of treatment options in heart disease but also addressing the substantial healthcare challenges that arise from conditions like recurrent pericarditis. As their Phase III study progresses, the company is reaffirming its commitment to enhancing patient outcomes in this vital medical frontier.

For further details regarding Cardiol Therapeutics and its range of therapies, visit cardiolrx.com.